Company Rani Therapeutics Holdings, Inc.

Equities

RANI

US7530181004

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
6.56 ^USD	-6.15%		+8.43%	+97.59%

Mar. 27	Canaccord Genuity Adjusts Rani Therapeutics Price Target to $9 From $21, Maintains Buy Rating	MT
Mar. 25	HC Wainwright Adjusts Price Target on Rani Therapeutics to $12 From $16, Keeps Buy Rating	MT

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. It has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. The RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-102, RT-105, RT-111 and RT-110. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC, which is intended to enable delivery of drug payloads up to 200uL in liquid form with high bioavailability.

Number of employees: 140

Managers	Title	Age	Since
Talat Imran CEO	Chief Executive Officer	43	21-05-31
Mir Imran FOU	Founder	68	21-04-05
Svai Sanford DFI	Director of Finance/CFO	53	21-04-05
Jacques Van Dam CTO	Chief Tech/Sci/R&D Officer	-	20-12-31
Mir Hashim CTO	Chief Tech/Sci/R&D Officer	65	21-04-05
Bella Vazquez HRO	Human Resources Officer	-	21-06-30
Eric Groen LAW	General Counsel	-	21-09-08
Kate McKinley PRN	Corporate Officer/Principal	-	23-05-23
Arvinder Dhalla PRN	Corporate Officer/Principal	-	21-06-30
J. Christopher Prue LAW	General Counsel	-	21-06-30

Members of the board	Title	Age	Since
Laureen DeBuono BRD	Director/Board Member	66	21-04-05
Jean-Luc Butel BRD	Director/Board Member	67	21-04-05
Dennis Ausiello BRD	Director/Board Member	78	21-04-05
Mir Imran FOU	Founder	68	21-04-05
Andrew Farquharson BRD	Director/Board Member	65	21-04-05
Talat Imran CEO	Chief Executive Officer	43	21-05-31
Maulik Nanavaty BRD	Director/Board Member	62	21-04-05
Mir Hashim CTO	Chief Tech/Sci/R&D Officer	65	21-04-05
Lisa Rometty BRD	Director/Board Member	-	22-01-02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	10	24,116,444	0	0	25.63 %
Stock B	1	29,298,553	13,690,556 ( 46.73 %)	3,000,000 ( 10.24 %)

Name	Equities	%	Valuation
South Cone Investments LP 46.59 %	12,131,554	46.59 %	38 M $
Vanguard Global Advisers LLC 2.567 %	668,347	2.567 %	2 M $
Pivotal Bioventure Partners Investment Advisor LLC 1.895 %	493,584	1.895 %	2 M $
Mir Imran 1.860 %	484,455	1.860 %	2 M $
United Services Automobile Association 1.848 %	481,300	1.848 %	1 M $
TEIJIN LIMITED 1.731 %	450,733	1.731 %	1 M $
ALPHABET INC. 1.722 %	448,492	1.722 %	1 M $
Eric Groen 0.6268 %	163,216	0.6268 %	507 602 $
Bank of America, NA (Charlotte, North Carolina) 0.4388 %	114,259	0.4388 %	355 345 $
Geode Capital Management LLC 0.4363 %	113,629	0.4363 %	353 386 $

Name	Equities	%	Valuation
Mir Hashim -	374,119	-	1 M $
Andrew Farquharson -	242,421	-	753 929 $
Maulik Nanavaty -	155,118	-	482 417 $
Svai Sanford -	142,350	-	442 709 $
Dennis Ausiello -	92,074	-	286 350 $
Talat Imran -	43,484	-	135 235 $

Name	Equities	%	Valuation
In-Cube, Inc. 76.57 %	22,411,124	76.57 %	70 M $
Andrew Farquharson 1.143 %	334,672	1.143 %	1 M $
Maulik Nanavaty 0.1807 %	52,878	0.1807 %	164 451 $
Mir Hashim 0.0876 %	25,649	0.0876 %	79 768 $

Rani Therapeutics Holdings, Inc.

2051 Ringwood Avenue

95131, San Jose

http://www.ranitherapeutics.com

address Rani Therapeutics Holdings, Inc.(RANI)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.56 USD

Average target price

8.857 USD

Spread / Average Target

+35.02%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
RANI THERAPEUTICS HOLDINGS, INC.	+97.59%	184M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs